Dabigatran Etexilate Shows Greater Reductions Than Warfarin in Stroke in Patients

Published March 16th, 2010 - 09:39 GMT
Dabigatran etexilate 150mg bid and dabigatran etexilate 110mg bid were both associated with lower major bleeding rates when compared with well-controlled warfarin in patients with AF at low risk of stroke. 1
INGELHEIM, Germany, March 15, 2010 (Business Wire / ME NewsWire): Data presented today at the 59th Annual Scientific Session of the American College of Cardiology have shown greater reductions in stroke in patients with atrial fibrillation (AF) for dabigatran etexilate* compared to the current standard of care, warfarin, irrespective of a patient’s risk profile for stroke.1 The new sub-group analysis from the landmark RE-LY® study** assessed the rate of stroke and systemic embolism in patients defined as being at low (n=5,775), moderate (n=6,455) and high (n=5,882) risk of such events by the validated stroke risk stratification score, CHADS2.1,2
The RE-LY® sub-group analysis showed that dabigatran etexilate 150mg bid reduced the rate of stroke and systemic embolism compared with well-controlled warfarin, irrespective of a patient’s stroke risk. Dabigatran etexilate 110mg bid resulted in similar reductions as well-controlled warfarin. Both doses were associated with lower major bleeding rates in patients at low risk of stroke.1
In detail, the results showed:1
• Dabigatran etexilate 150mg bid reduced the rate of stroke and systemic embolism when compared with well-controlled warfarin across all stroke risk groups with the relative risk (RR) being 0.62 (0.38−1.02) in low, 0.61 (0.40−0.92) in moderate, and 0.70 (0.52−0.95) in high risk patients
Dabigatran etexilate 110mg bid showed similar reductions in the rate of stroke and systemic embolism to well-controlled warfarin, with RR being 1.00

© 2000 - 2019 Al Bawaba (www.albawaba.com)

You may also like